Empowering patients to actively manage their treatment at-home with personalized digital solutions.
Aptar Digital Health Joined The White House CancerX Moonshot Project.
By joining this initiative, we aim to create, foster, accelerate, and scale the impact of a community of innovators dedicated to reducing the burden of cancer for all people.
Why develop digital health initiatives in oncology?
At Aptar Digital Health, we believe that giving the right support to patients can make a difference in their treatment experience. As a result of unmet medical needs, cancer care requires unique attention, close monitoring, and personalization of care pathways.
These needs are a result of:
Complex and individualized treatment plans
High toxicity profiles leading to side effects that impact the quality of life
Insufficient access to supportive care
Innovative therapies can be complex to administer and monitor. The transition from hospital to home requires a high level of engagement from patients, and experiencing side effects is unfortunately very common.
This is why our approach to oncology enables the active participation of each patient in the self-administration of treatments when possible, and self-management of their symptoms, helping increase treatment adherence and ultimately experience more positive outcomes.
Discover our approach in oncology.
Aptar Digital Health develops customized, end-to-end digital therapeutics for oncology, accessible through a mobile app for patients and EHRs and web portals for care teams.
While starting a new treatment or undergoing therapy, patients can use their phone to input symptom details in the app in order to receive real-time, actionable recommendations according to their current condition and treatment profile. Once patients enter their data, the clinical algorithms engine assesses the patient’s situation and immediately provides personalized recommendations to guide their symptom management and support remote monitoring by their care team.
By leveraging embedded evidence-based clinical algorithms, our solutions can help patients:
Identify, qualify, and report their symptoms
Actively manage their symptoms
Gain knowledge about their disease and confidence in managing their treatment
Understand when they need to contact their care team
By providing automatic, actionable feedback, our digital therapeutics are designed to enhance patient experiences, while the automated monitoring of common side effects enable care teams to focus on the most critical cases. For each patient, the assessment of symptom severity is based on their individual profile and care plan configured by the care team.
When relevant, patients are guided through each self-administration of their treatment to provide clarity and confidence. Seamlessly integrated with our connected drug delivery devices, our digital therapeutics allow patients to evaluate the effectiveness of their injection, while automatically sending adherence data to their care team.
With this digital solution at their fingertips, patients can also access educational content, such as info cards and curated articles from reliable sources, to better understand their disease and symptoms.
Using the unique dataset generated by the digital solution, our technology can analyze and identify trends for each patient, simplifying and enhancing the remote monitoring process for care teams. The overall goal is to increase treatment adherence, strengthen the relationship between the patient and their care team, and improve the quality of life — all while reducing healthcare costs.
Testimonials
“the app seems very informative…very easy…has a simple layout & looks awesome “
the app is clear and easy to use for someone like me
The first-in-class digital therapeutic in oncology
authorized in the US and Europe.
Oleena® is a prescription mobile app intended for use by healthcare professionals and their adult patients with cancer as an aid for the management of symptoms experienced during the oncology treatment phase. Before use, please carefully read product instructions available in the “More” tab of the app. Oleena is not to be used during pregnancy and by patients under 18 years old. Oleena is a registered trademark of Voluntis. For distribution in the US only.
A feasibility study for patients with ovarian cancer.
In collaboration with AstraZeneca and the US National Cancer Institute (NCI) through clinical trials of cediranib in combination with olaparib, we developed eCO*, a digital therapeutic for women undergoing treatment for recurrent platinum-sensitive, high-grade ovarian cancer. eCO was designed to self-report and manage hypertension and diarrhea using remote monitoring. In 2018, the results were published in JCO Clinical Cancer informatics. The authors (J.Liu et al), highlighted feasibility, usability, and perceived satisfaction with the use of the digital therapeutic and related healthcare team web portal.
In regard to the use of the eCO app, patients reported positive feedback, indicating they felt more involved in their care and better connected with their healthcare team. Hypertension and diarrhea events reported via the eCO app allowed rapid response and positive overall patient experience.
Symptom management is a key area of improvement for patients, HCPs, health systems:
98%
eCO captured 98.2% of required blood pressure measures*
87%
87% of diarrhea events limited to grade 1
*eCO is a digital therapeutic for patients with ovarian cancer that has been designed for investigational purposes. eCO is not commercially available.
* to process your contact request. If you do not fill them in, your request cannot be processed. To find out more about the use of your personal data and how to exercise your rights, please consult the Privacy Policy
